Primary vitreoretinal lymphoma (PVRL), also known as primary intraocular lymphoma (PIOL), is a subset of primary central nervous system lymphoma (PCNSL), typically diffuse large B-cell lymphoma, which often manifests as posterior uveitis or sub-retinal pigment epithelial (RPE) infiltrates. 1 PCNSL treatment includes radiation and chemotherapy; however, the optimal therapy for PVRL without CNS involvement is unknown. 2 We report the efficacy of intravitreal rituximab and methotrexate in a patient with PVRL who presented with massive sub-retinal infiltration with RPE involvement.
Case report
An 83-year-old male patient presented with a 1-month history of progressive blurred vision OS. Visual acuities were 20/20 OD and hand motions OS. A relative afferent pupillary defect was present OS. Ophthalmic examination was normal OD. Trace vitritis and diffuse, confluent yellow-white subretinal infiltrates were seen OS ( Figure 1) . CBC, RPR, FTA-ABS, HIV, ACE, ESR, and chest CT scan were normal. Pars plana vitrectomy, subretinal aspiration biopsy, air-fluid exchange, endolaser, and 14% C 3 F 8 instillation were performed.
Cytopathology revealed lymphomatous infiltrates with condensed chromatin and multiple nucleoli. Flow cytometry showed CD20 þ staining. IgH gene rearrangement studies demonstrated monoclonal restriction consistent with diffuse large B-cell lymphoma.
Brain MRI and CSF studies were negative for CNS disease. Following neuro-oncology consultation regarding treatment options including chemotherapy, blood-brain barrier disruption, and radiation, systemic therapy was deferred by the patient. Monthly intravitreal injections of rituximab (1 mg/0.1 ml) and methotrexate (400 mcg/0.1 ml) for 3 months were undertaken. Rapid regression of the subretinal lesions was observed by 2 months and visual acuity improved to finger counting at 3 feet. The retinal examination was stable at 18 months with no evidence of CNS involvement.
Comment

Rituximab is a chimeric monoclonal antibody targeting the CD20
þ B-cell marker, while methotrexate inhibits folate metabolism and DNA synthesis. Intravitreal monotherapy for PIOL has been described, [3] [4] [5] while combination intravitreal methotrexate 200 mg/0.05 ml (half the standard dose) and rituximab 1 mg/0.1 ml has been reported once previously. 4 The rationale for combination therapy stems from conventional combination chemotherapy for systemic diffuse large B-cell lymphoma, which may include high-dose systemic methotrexate and intrathecal rituximab. 6 The complete ocular remission in our patient following three doses of combination methotrexate and rituximab at 18-months follow-up suggests that this dosing strategy warrants further investigation. Further studies are needed to determine its long-term efficacy, and CNS surveillance with the aid of a neuro-oncologist is advisable. 4 We re-evaluated the data from this study to investigate the associations of opacification with patient, surgical, and lens-related factors. Data were gathered through a review of medical records, patient interview, and examination.
Data from 215 patients who had Hydroview lenses implanted in Bristol were analysed: 125 had clear lenses, 89 had evidence of opacification, and 1 lens could not be assessed. No statistically significant association was demonstrated between opacification and any of the patient- (Tables 1 and 2 ) or surgery-related factors (Table 3) tested. However, this is likely to be a result of the small number of patients at subgroup analysis level.
There was a marked association of opacification with certain runs of consecutive lens serial numbers (Table 4) . Serial numbers relate only to the order in which the lenses are manufactured and are sequential. Our study will have selection bias, as all patients had surgery over a similar time period and those symptomatic would be more likely to enrol. There will be a high number of certain runs of serial numbers and a high number of opacified lenses. However, variation in the proportion of lenses opacified (3-79%) across the serial numbers tested strongly suggests an association between opacity and certain runs of serial numbers.
Although these data must be viewed with respect to the context, ie, as a retrospective observation rather than as prospective evidence, they do question the supposition that the sole cause for opacification was the 
